Bristol-Myers Squibb Company Reports Financial Results

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) reported financial results for the third quarter and nine months ended September 30, 2007 and updated earnings guidance for the full year. The company posted third quarter 2007 net sales of $5.1 billion, an increase of 22% over the same period in 2006.

Bristol-Myers Squibb reported third quarter 2007 net earnings of $858 million, or $0.43 per diluted share, under U.S. Generally Accepted Accounting Principles (GAAP), compared to $338 million, or $0.17 per diluted share for the same period in 2006. The 2007 results include a one-time pre-tax gain of $247 million ($144 million net of tax, or $0.07 per diluted share) on the sale of the BUFFERIN® and EXCEDRIN® brands in Japan. On a non-GAAP basis excluding specified items, third quarter 2007 net earnings were $764 million, or $0.38 per diluted share, compared to $438 million, or $0.22 per diluted share for the same period in 2006. The increase in net earnings in 2007 as compared to 2006 is due to strong sales growth of key and newer products in 2007 and reflects the adverse impact of generic competition for PLAVIX® in the third quarter of 2006.

"We remain focused on developing breakthrough medicines for patients worldwide, while also delivering shareholder value," said James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "We're making significant progress in identifying ways to operate more efficiently and reduce costs companywide as we maintain investments in our productive pipeline, which continues to yield important new therapies, including the recent addition of IXEMPRA® for breast cancer. We're also boosting our presence in biologics with the announced acquisition of Adnexus Therapeutics. Our key products continue to demonstrate solid growth as we move forward with the transformation of our pharmaceutical business to help even more people prevail in their fight against serious diseases."

For the nine months ended September 30, 2007, net sales increased 5%, including a 2% favorable foreign exchange impact, to $14.5 billion compared to the same period in 2006. Net earnings in the first nine months of 2007 on a GAAP basis were $2.3 billion, or $1.14 per diluted share, compared to $1.7 billion, or $0.88 per diluted share for the same period last year. On a non-GAAP basis, excluding specified items, Bristol-Myers Squibb reported net earnings of $2.2 billion, or $1.13 per diluted share for the nine months ended September 30, 2007, compared to $1.8 billion, or $0.89 per diluted share for the same period last year.

For further information, visit http://www.bms.com.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. For more information, visit www.bms.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]